Benitec Biopharma (BNTC) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Benitec Biopharma (BNTC) over the past year, losing 38.6% versus a loss of 40.3%. Over five years, BNTC leads with a -85.7% price change compared with -86.1% for RLMD. Benitec Biopharma is the larger company by market cap ($285.9 million vs $279.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | RLMD |
|---|---|---|
| Share price | $7.92 | $2.62 |
| Market cap | $285.88M | $279.54M |
| 1-day change | -2.76% | -15.76% |
| YTD return | -41.24% | -45.76% |
| 1-year return | -40.31% | -38.64% |
| 5-year return | -85.67% | -86.09% |
| EPS (TTM) | $-1.02 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-45.55M | $-57.39M |
| 52-week high | $14.39 | $8.00 |
| 52-week low | $7.72 | $2.60 |
| Distance from 52-week high | -45.00% | -67.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +200.06% | +310.31% |
| Average volume | 174.01K | 1.45M |
| Shares outstanding | 36.12M | 106.69M |
| Employees | 24 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
BNTC vs RLMD FAQ
Which is bigger, Benitec Biopharma or Relmada Therapeutics?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $285.88M compared with $279.54M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, BNTC or RLMD?
RLMD returned -38.64% over the past 12 months, compared with -40.31% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.